Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Osimertinib mesylate by AstraZeneca for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Osimertinib mesylate is under clinical development by AstraZeneca and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According...
Osimertinib mesylate by AstraZeneca for Refractory Multiple Myeloma: Likelihood of Approval
Osimertinib mesylate is under clinical development by AstraZeneca and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData,...
Osimertinib mesylate by AstraZeneca for Lymphoma: Likelihood of Approval
Osimertinib mesylate is under clinical development by AstraZeneca and currently in Phase II for Lymphoma. According to GlobalData, Phase II...
Osimertinib mesylate by AstraZeneca for Non-Small Cell Lung Carcinoma: Likelihood of Approval
Osimertinib mesylate is under clinical development by AstraZeneca and currently in Phase II for Non-Small Cell Lung Carcinoma. According to...
Osimertinib mesylate by AstraZeneca for Non-Small Cell Lung Carcinoma: Likelihood of Approval
Osimertinib mesylate is under clinical development by AstraZeneca and currently in Phase II for Non-Small Cell Lung Carcinoma. According to...